Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53

Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53

Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) is a rare but heterogeneous subtype of MDS/MPN, with no specific genetic alterations and standard treatments. ASXL1, SRSF2, TET2, JAK2 and NRAS are commonly mutated in MDS/MPN-U. Double gene mutations could be detected in MDS/MP...

Full description

Bibliographic Details
Main Authors: Qian Wang, Hai-ping Dai, Dan-dan Liu, Jun-dan Xie, Hong Yao, Zi-xuan Ding, Ting-ting Tao, Su-ning Chen, Ri Zhang
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:Leukemia Research Reports
Subjects:
Myelodysplastic/myeloproliferative neoplasm-unclassifiable
Ruxolitinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048920300352

Similar Items

Similar Items